Lipoprotein(a) variability in high CV risk patients with hypertriglyceridemia and controlled LDL-C on statin therapy – REDUCE-IT Lp(a) Variability
Therapeutics that dramatically lower lipoprotein(a) (Lp(a)) currently in phase 3 testing have enrolled participants with concentrations above certain thresholds, e.g., ≥70 mg/dL or ≥150 nmol/L. Although repeated testing of Lp(a) is generally viewed as unnecessary due to the fact that concentrations are primarily...